This finding fits with recent data showing that the symptomatic phase of AD is characterized by a decrease in CSF tau levels [188]; this may relate to a slowing in neuronal loss and/or the sequestration of p-tau in tangles [186]. The gene discussed is MAPT; the disease is Alzheimer disease.